Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Inozyme Pharma Inc.
Sponsor

Inozyme Pharma Inc.

United States 321 Summer Street, 02210-1725, United States

About the sponsor

Inozyme Pharma Inc. focuses on inherited disorders linked to disrupted pyrophosphate metabolism, with research centered on ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) deficiency. Its clinical program addresses both isolated and overlapping forms of these rare mineralization disorders.

  • ENPP1 deficiency
  • ABCC6 deficiency
  • Combined ENPP1 or ABCC6 deficiency

The research activity in this area is directed toward conditions associated with abnormal tissue calcification and impaired regulation of inorganic pyrophosphate (PPi).

About Specializations

Inozyme Pharma Inc. runs clinical trials in conditions such as Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency, Arteriosclerosis, Pseudoxanthoma elasticum, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Arteriosclerosis+2

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency

Not recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Arteriosclerosis+1

Not recruiting
InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.